Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLEC2D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLEC2D ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CLEC2D Products |
| Gene Delivery | CLEC2D Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based binding assays. |
View CLEC2D Products |
| Benchmark Ab | Anti-CLEC2D Recombinant Antibody Recombinant positive control for flow cytometry and blocking assays. |
View CLEC2D Products |
| Validator | CLEC2D siRNA Set For target knockdown validation in functional co-culture assays. |
View CLEC2D Products |
| Related Target A | KLRB1 (CD161) The primary functional receptor for CLEC2D; crucial for validating ligand-receptor blockade. |
View KLRB1 Products |
| Related Target B | CLEC2C (AICL) Closely related subfamily member; essential for counter-screening to ensure antibody selectivity. |
View CLEC2C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native glycosylation for receptor binding | Exclusively HEK293-expressed recombinant proteins ensuring post-translational modifications. |
| Subfamily cross-reactivity (Off-target risks) | Homolog panel proteins (CLEC2A, CLEC2C) strictly verified by mass spectrometry for selectivity assays. |
| Lack of clinical-grade reference controls | Sequence-verified benchmark antibodies synthesized as high-fidelity biosimilars. |
| Target validation in primary cells | Sequence-verified siRNA pool available for highly specific knockdown in human primary immune cells. |
Live CLEC2D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLEC2D therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific/multispecific antibodies and combination regimens. As first-generation therapies targeting the KLRB1-CLEC2D axis reach the clinic, the next wave of R&D is targeting the immunosuppressive tumor microenvironment (TME) in solid tumors, particularly glioblastoma and prostate cancer, where CLEC2D is highly upregulated on tumor-associated macrophages (TAMs).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Bristol Myers Squibb, Biotech startups | Glioblastoma, Triple-Negative Breast Cancer | High-purity CLEC2D ECD-Fc for SPR-based affinity determination and ligand blocking. |
| Bispecific / NK Engagers | Academic Institutes, Immunotherapy players | Hematological malignancies, Solid tumors | Simultaneous binding assays requiring high-purity KLRB1 and CLEC2D target proteins. |
| Cell Therapies (CAR-NK) | Next-gen CAR-NK developers | Refractory solid tumors | Lentivirus-mediated stable cell lines expressing CLEC2D for target-cell killing assays. |